Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...
News-Medical.Net on MSN
Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...
In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.
Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx 1; This Columvi combination is available off-the-sh ...
Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...
With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1Data ...
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025 ...
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...
Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...
Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback